Renovaro Biosciences Statistics
Share Statistics
Renovaro Biosciences has 158.72M shares outstanding. The number of shares has increased by 178.57% in one year.
| Shares Outstanding | 158.72M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -4.17% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 77.15M |
| Failed to Deliver (FTD) Shares | 9.02K |
| FTD / Avg. Volume | 1.38% |
Short Selling Information
The latest short interest is 3.23M, so 2.04% of the outstanding shares have been sold short.
| Short Interest | 3.23M |
| Short % of Shares Out | 2.04% |
| Short % of Float | 4.11% |
| Short Ratio (days to cover) | 4.72 |
Valuation Ratios
The PE ratio is -1.86 and the forward PE ratio is null.
| PE Ratio | -1.86 |
| Forward PE | null |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 1.14 |
| P/FCF Ratio | -13.6 |
| PEG Ratio | n/a |
Enterprise Valuation
Renovaro Biosciences Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 0.07, with a Debt / Equity ratio of 0.02.
| Current Ratio | 0.07 |
| Quick Ratio | 0.07 |
| Debt / Equity | 0.02 |
| Total Debt / Capitalization | 1.82 |
| Cash Flow / Debt | -4.48 |
| Interest Coverage | -80.73 |
Financial Efficiency
Return on equity (ROE) is -0.61% and return on capital (ROIC) is -60.13%.
| Return on Equity (ROE) | -0.61% |
| Return on Assets (ROA) | -0.49% |
| Return on Capital (ROIC) | -60.13% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -3.23M |
| Employee Count | 25 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -50% in the last 52 weeks. The beta is 0.54, so Renovaro Biosciences 's price volatility has been higher than the market average.
| Beta | 0.54 |
| 52-Week Price Change | -50% |
| 50-Day Moving Average | 0.73 |
| 200-Day Moving Average | 1.3 |
| Relative Strength Index (RSI) | 71.02 |
| Average Volume (20 Days) | 655.75K |
Income Statement
In the last 12 months, Renovaro Biosciences had revenue of $0 and earned -$80.65M in profits. Earnings per share was $-0.84.
| Revenue | 0 |
| Gross Profit | -121.86K |
| Operating Income | -81.64M |
| Net Income | -80.65M |
| EBITDA | -79.52M |
| EBIT | - |
| Earnings Per Share (EPS) | -0.84 |
Balance Sheet
The company has $220.47K in cash and $3.79M in debt, giving a net cash position of -$3.57M.
| Cash & Cash Equivalents | 220.47K |
| Total Debt | 3.79M |
| Net Cash | -3.57M |
| Retained Earnings | -324.68M |
| Total Assets | 121.83M |
| Working Capital | -21.09M |
Cash Flow
In the last 12 months, operating cash flow was -$10.97M and capital expenditures -$70.43K, giving a free cash flow of -$11.04M.
| Operating Cash Flow | -10.97M |
| Capital Expenditures | -70.43K |
| Free Cash Flow | -11.04M |
| FCF Per Share | -0.11 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
RENB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -47.46% |
| FCF Yield | -3.93% |
Analyst Forecast
Currently there are no analyst rating for RENB.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | -1.65 |
| Piotroski F-Score | 2 |